Clearside Biomedical to Present at the Needham Virtual Healthcare Conference

ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at the Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45 p.m. ET.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:Jenny Kobin Remy Bernarda [email protected](678) 430-8206

Source: Clearside Biomedical, Inc.

You May Also Be Interested In

• Instruqt Becomes the First and Only Platform to Pair AI-Assisted Content Creation with Native Vertex AI, Amazon Bedrock, and GPU Environments
• LBank Delivers Exclusive World Cup Private Suite Experience, Bringing Global VIP Users and Partners Together in Dallas
• WISeKey and Its Subsidiary WISeSat.Space Corp. Announce Filing of Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission